(UroToday.com) In this presentation, Dr. Enrique Grande discussed the results of the GETUG/AFU VESPER V05 Phase III Trial and the Phase II trial of pembrolizumab plus sEphB4-HSA in metastatic urothelial carcinoma (UC). These two studies led to exciting results with the potential to impact practice for patients with urothelial carcinoma in the future.